Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (494 records) with 2024 (311) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 9,460 records in scope (CR5), not by the ranked leaders only.
Lyophilized biologic formulation sits at the intersection of drug product formulation and process engineering: how a protein, peptide or vector-based biologic is dried, stored and reconstituted without losing potency. The search underlying this landscape combines formulation language — lyophilized formulation, cake appearance, freeze drying cycle — with the process and quality variables that determine whether a cycle actually works at scale: collapse temperature, residual moisture, reconstitution time, annealing step, vial heterogeneity and cycle robustness.
The dataset spans 9,460 published records filed between 2015 and mid-2026. Because publication trails filing by roughly 18 months, the most recent one to two years understate real filing activity and should be read as provisional rather than a sign of decline.
Two views of the same 9,460-record corpus: how filing volume has moved year over year, and how claims distribute across IPC subclasses.
Filings peaked in 2017 at 549 records. The 2021-to-2024 window, the last stretch with complete publication, shows a 37% decline from 494 to 311 records — a real contraction in new claim activity, not an artefact of publication lag.
A61K (medicinal preparations) appears on 87.9% of records and C07K (peptides and proteins) on 32.9%, confirming this is primarily a formulation-composition field. G01N (material analysis and testing), C07D (heterocyclic compounds) and C07H (sugars and nucleic acids) each sit under 3%, which is thin given how central moisture and cake-structure analytics are to cycle development.
Shares are the percentage of the 9,460 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about lyophilized biologic formulation and every answer comes back with the patent numbers behind it.
Try EurekaThe present invention provides methods for assessing and optimizing lyophilization cycle robustness. In particular, the present invention provides rapid assessment of cycle robustness with respect to a variety of lyophilization process deviations by varying a relatively small number of parameters.Framed as a process-robustness method rather than a composition claim, this filing sits upstream of formulation-specific patents — it constrains how cycle deviations are tested, not which excipients are used.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6267958B1 | Protein formulation | 3,205 |
| 2 | WO1997004801A1 | Stabile isotonic lyophilized protein formulation | 1,403 |
| 3 | US5814482A | Eukaryotic layered vector initiation systems | 995 |
| 4 | WO1995007994A2 | Recombinant alphavirus vectors | 776 |
| 5 | WO1996017072A2 | Recombinant alphavirus vectors | 746 |
| 6 | US6685940B2 | Protein formulation | 621 |
| 7 | US5385887A | Formulations for delivery of osteogenic proteins | 526 |
| 8 | US5843723A | Alphavirus vector constructs | 511 |
| 9 | US5789245A | Alphavirus structural protein expression cassettes | 495 |
| 10 | US20040197324A1 | High concentration antibody and protein formulations | 478 |
Citation counts accumulate over time and favour older filings; treat them as a signal of influence on later work, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three findings that shape where new claims can still land and who is actively defending ground.
The leader holds 522 records against a corpus of 9,460, and even the combined top ten account for less than a third of all records. This is a field with a long tail of single- and few-filing entrants rather than a two- or three-way standoff.
Recent-year momentum for the most active assignees is uniformly negative — several show year-on-year declines of 56% or more, and multiple leaders show zero filings in the latest year. That pattern, combined with the corpus-wide 2021-to-2024 drop, suggests consolidation of existing IP rather than fresh land-grabbing.
Formulation composition (A61K) and biologic-specific classes (C07K, A61P) dominate claim activity. Material analysis and testing (G01N) sits at only 2.9% of records, despite residual moisture and cake-structure measurement being central to cycle validation — a gap between what the science requires and what has been claimed.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lyophilized biologic formulation, with the prior art for and against each one.
The ranked leaders in this dataset are large biologics originators — consistent with a field where formulation IP protects marketed products rather than platform technology.
The top-ranked assignee holds 522 records, roughly double the fifth-place figure of 250 and nearly triple the tenth-place figure of 178 — a gradual taper rather than a cliff.
Only ten co-assignee pairs appear in the dataset, and the strongest pairing far outweighs the others — most filers here protect formulation IP independently rather than through joint filings.
The United States leads receiving offices at 1,734, ahead of the EPO at 1,184 and WIPO/PCT filings at 867, with Australia, Israel and Canada each in the 500-to-800 range — a filing footprint that tracks major biologics regulatory markets rather than a single dominant jurisdiction.
| Assignee | Recent year | YoY |
|---|---|---|
| Takeda Pharmaceutical Company Limited | 4 | -56% |
| Genentech, Inc. | 1 | -83% |
| Novartis AG | 0 | -100% |
| Bristol-Myers Squibb Company | 0 | -100% |
| Shire Human Genetic Therapies, Inc. | 0 | — |
| F. Hoffmann-La Roche AG | 0 | — |
| Millennium Pharmaceuticals, Inc. | 0 | -100% |
| Regeneron Pharmaceuticals, Inc. | 0 | -100% |
The trend and composition data point to where claim space is open, but a filing decision needs claim-level comparison against the specific art in a target sub-area.
Formulation composition claims are dense; a new filing needs to be checked against the specific excipient, buffer or lyoprotectant combination it covers, not just the broad category.
Run a freedom-to-operate check in EurekaTesting and measurement claims (residual moisture, cake structure, vial heterogeneity) are comparatively thin relative to composition claims — a candidate area for new process-method filings.
Explore white space in EurekaSeveral leading assignees show sharp year-on-year declines in filing volume; confirming whether that reflects portfolio maturity or a shift to trade secrecy changes how competitive that ground really is.
Monitor assignee activity in EurekaIt is only moderately concentrated. The five most active assignees together hold 19.4% of the 9,460 records in scope, and the ten most active hold 30.6%. That leaves the majority of records spread across a long tail of assignees with only a handful of filings each, so the field is not controlled by one or two dominant players. A new entrant should expect to negotiate around several mid-sized portfolios rather than a single gatekeeper.
Filing peaked in 2017 at 549 records and has since pulled back. Looking at the most recent complete years, 2021 to 2024, filings fell 37%, from 494 to 311. Note that 2025 and later years will look artificially low in any raw count because publication typically lags filing by around 18 months, so those years should not yet be read as a continuation of the decline.
A61K, medicinal preparations, appears on 87.9% of the 9,460 records, making it by far the dominant class. C07K (peptides and proteins) and A61P (therapeutic activity of compounds) each appear on roughly a third of records. Classes tied to process analytics and testing, such as G01N, appear on under 3% of records, indicating that most claim activity protects formulation composition rather than the measurement methods used to validate a cycle.
US20090324586A1, assigned to Wyeth LLC, describes methods for assessing and optimizing lyophilization cycle robustness by varying a small number of process parameters to rapidly test a cycle's tolerance to deviations. It is a process-methodology filing rather than a composition-of-matter claim, so it does not block specific excipient or buffer formulations. It does, however, sit upstream of formulation work by covering how cycle robustness itself is tested, which is relevant to anyone validating a lyophilization process rather than just formulating the biologic.
The clearest gap is between dense composition claims and thin process-analytics claims. Areas such as residual moisture measurement, vial-to-vial heterogeneity detection, annealing-step process control and cake-appearance or collapse-temperature analytics collectively account for only a few percent of records despite being central to cycle validation. That gap suggests new filings framed around measurement and process-control methods, rather than new excipient combinations, face less prior art density.
The ranked leaders are large biologics originators, with the top assignee holding 522 records against a corpus of 9,460 and a gradual taper down to 250 records at fifth place and 178 at tenth. Several of these leading assignees show sharply negative year-on-year filing momentum in the most recent year, some down more than 50%, which may reflect portfolio maturity as much as reduced R&D investment in this specific formulation problem.
Go past this page: query the whole lyophilized biologic formulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page